https://www.auntminnie.com/clinical-news/molecular-imaging/article/15670434/blue-earth-diagnostics-blue-earth-siemens-ink-deal-for-posluma-clinical-trial
Blue Earth, Siemens ink deal for Posluma clinical trial
Blue Earth Diagnostics, a Bracco company, has signed a nonexclusive data-sharing agreement with Siemens Healthineers.
For its syngo.via platform, Siemens plans to evaluate anonymized clinical data and images from Blue Earth's Posluma (flotufolastat F-18) injection (formerly known as F-18 rhPSMA-7.3) phase III Lighthouse study, an open-label, prospective, phase III, multicenter, single-dose imaging study investigating the safety and diagnostic performance of Posluma PET imaging in men with newly diagnosed prostate cancer. The study enrolled 356 patients at clinical sites in the U.S. and Europe.
Siemens will utilize the Lighthouse data to improve its analytics and AI-based algorithms for prostate cancer image quantification and interpretation across its PET/CT imaging software, according to the vendor.
Blue Earth said it also plans to make analytical data from the phase III Spotlight trial of Posluma available in the future. That study was an open-label, prospective, phase III, multicenter, single-dose imaging study investigating the safety and efficacy of Posluma PET imaging in men with suspected prostate cancer recurrence. The study enrolled 391 patients at clinical sites in the U.S. and Europe.
https://www.siemens-healthineers.com/digital-health-solutions/syngovia
Let’s advance the digitalization of healthcare with syngo.via. As an intelligent, integrated imaging software, syngo.via helps you address and overcome these issues. With syngo.via, we focus on streamlining the processes around reading and reporting. syngo.via unifies and centralizes intelligent tools in a powerful diagnostic workflow to make your routine tasks more convenient and efficient. At the same time, syngo.via optimizes report creation by integrating established solution with real-time findings transfer. It delivers actionable image-based results that are consolidated in one high-quality report.
- Forums
- ASX - By Stock
- TLX
- Ann: Presentation to Accompany AI Development Program Update
Ann: Presentation to Accompany AI Development Program Update, page-68
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.63 |
Change
0.140(0.68%) |
Mkt cap ! $6.904B |
Open | High | Low | Value | Volume |
$20.37 | $20.63 | $20.01 | $23.18M | 1.138M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 494 | $20.58 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.63 | 676 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 494 | 20.580 |
1 | 3342 | 20.430 |
1 | 3342 | 20.400 |
1 | 11859 | 20.380 |
1 | 3342 | 20.360 |
Price($) | Vol. | No. |
---|---|---|
20.630 | 676 | 1 |
20.640 | 3342 | 1 |
20.650 | 350 | 1 |
20.670 | 11859 | 1 |
20.680 | 3492 | 3 |
Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online